Displaying drugs 13026 - 13050 of 14363 in total
BMN-351
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
GX-G8
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Ilixadencel
Investigational
GRObeta
Investigational
Osemitamab
Investigational
Tagitanlimab
Investigational
TSHA-104
Investigational
XMT-2056
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
AP103
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
TLR-AD1
Investigational
Human autologous bone marrow derived osteoblastic cells
Investigational
Human glial progenitor cells
Investigational
HM15912
HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.
Investigational
LX2006
Investigational
SP-101
Investigational
OT-004
Investigational
CT-001
Investigational
AO-176
Investigational
Ulenistamab
Investigational
CM-101
Investigational
4D-110
Investigational
JAG101
Investigational
4D-310
4D-310 is a adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene
Investigational
Displaying drugs 13026 - 13050 of 14363 in total